Gene · 10644
IGF2BP2: insulin like growth factor 2 mRNA binding protein 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. IGF2BP2: insulin like growth factor 2 mRNA binding protein 2. Genes, record 10644. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/10644
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9Y6M1 | Insulin-like growth factor 2 mRNA-binding protein 2 | 599 | 4 | Ensembl, GeneID, HGNC |
Source UniProt
Patents27
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 49919 | Q9Y6M1 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 10531 | Q9Y6M1 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 10531 | Q9Y6M1 | Espacenet |
| US 12023371 B2 | 2024-07-02 | 4649 | Q9Y6M1 | Espacenet |
| JP 2023533815 A | 2023-08-04 | 19 | Q9Y6M1 | Espacenet |
| KR 1020230068378 A | 2023-05-17 | 19 | Q9Y6M1 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 40589 | Q9Y6M1 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 143560 | Q9Y6M1 | Espacenet |
| US 10925935 B2 | 2021-02-23 | 4649 | Q9Y6M1 | Espacenet |
| WO 2020043864 A1 | 2020-03-05 | 1179 | Q9Y6M1 | Espacenet |
1 to 10 of 27
See all 27 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,711
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | IGF2BP2 papers | Newest fiscal year |
|---|---|---|---|
| ZIAHG000024 | Genetic analysis of type II diabetes | 14 | 2025 |
| P30DK020572 | Michigan Diabetes Research Center (MDRC) | 12 | 2025 |
| P30DK063491 | Diabetes Research Center (DRC) | 10 | 2025 |
| R01DK062370 | Identifying Genes for Type 2 Diabetes: FUSION | 10 | 2025 |
| R01HL086694 | From GWAS loci to blood pressure genes, variants & mechanisms - Renewal | 10 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 7 | 2025 |
| P30ES010126 | UNC Center for Environmental Health and Susceptibility | 7 | 2025 |
| R01DK093757 | Genetic epidemiology of rare and regulatory variants for metabolic traits | 7 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 5 | 2025 |
| P30DK017047 | Diabetes Research Center | 5 | 2025 |
1 to 10 of 1,711Source NIH's project files
See all 1,711 nih grantsPapers3,666
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
Statement of Retraction: N6-methyladenosine reader YTH N6-methyladenosine RNA binding protein 3 or insulin like growth factor 2 mRNA binding protein 2 knockdown protects human bronchial epithelial cells from hypoxia/reoxygenation injury by inactivating p38 MAPK, AKT, ERK1/2, and NF-κB pathways. | Bioengineered | 2026 | 42826084 | PubTator, text mining | PubMed |
| Statement of Retraction: N6-methyladenosine (m6A) reader IGF2BP2 promotes gastric cancer progression via targeting SIRT1. | Bioengineered | 2026 | 42821770 | PubTator, text mining | PubMed |
| An IGF2BP2-MYBL2-HMGB2 Signaling Axis Promotes Macrophage Immune Evasion in Hepatocellular Carcinoma. | Cancer Commun (Lond) | 2026 | 42819712 | PubTator, text mining | PubMed |
| METTL3 Increases Temozolomide Resistance in MGMT-Negative Glioblastoma by Enhancing CBX5 mRNA Stability in an m6A-IGF2BP2-Dependent Manner. | CNS Neurosci Ther | 2026 | 42817804 | PubTator, text mining | PubMed |
| SH2B3 Promotes PD-L1-Mediated Immune Evasion in Glioblastoma via BRCC3-Dependent IGF2BP2 Stabilization. | Int J Biol Sci | 2026 | 42807322 | PubTator, text mining | PubMed |
| Sublethal heat stress-induced HSF4 upregulation via GRSF1 in an m6A-dependent manner in hepatocellular carcinoma. | Chin Med J (Engl) | 2026 | 42754818 | PubTator, text mining | PubMed |
| CircRHBDD1(4,5) drives malignant progression of oral squamous cell carcinoma by enhancing DKK1 mRNA stability through facilitating m6A-dependent IGF2BP2 binding. | Oncogene | 2026 | 42722719 | PubTator, text mining | PubMed |
| Correction: METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma. | Mol Cancer | 2026 | 42701193 | PubTator, text mining | PubMed |
| METTL3-m6A-IGF2BP2 Axis-Mediated Stabilization of MTFR1 Promotes Glycolytic Reprogramming in Colorectal Cancer. | J Gastroenterol Hepatol | 2026 | 42681996 | PubTator, text mining | PubMed |
| The insulin-like growth factor 2 mRNA-binding protein 2 affects tumor cell metabolism via mitochondrial transporter activity and lipid alterations. | Cell Death Discov | 2026 | 42680753 | PubTator, text mining | PubMed |
1 to 10 of 3,666
See all 3,666 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/10644
GET https://conductscience.org/api/genes/v1/10644/patents?page=2